HomeAbout UsContact Us
Advanced Search
All CoursesCourses by TopicCourses by SpecialtyCourses by Specialty CreditRegister Now!!
Register Now!!
Member Login
Your Account
Your Test History
Your Certificates
Your Payment History
All Courses
Courses by Topic
Courses by Specialty
Courses by Specialty Credit
Accreditation
State Requirements
FAQs
 
Home : Advanced Search : Course view :






Course: Combination Treatment with Low-Dose Protracted Temozoloamide and Bevacizumab for Heavily Pretreated Patients with Recurrent Glioblastoma 


Specialty: Hematology/Oncology Format: Text 
Course #: 10535  Price: $20.00  
Release date: 2012-04-01  Valid through: 2015-04-01  
Publication: This activity originally appeared in Clinical Oncology Alert. 
Course viewing requirements (opens in a new window)
Instructions for Course Participation (opens in a new window)
Legal disclaimer (opens in a new window)


Target Audience:
This activity is intended for the oncologist.
Sponsor:
This activity is sponsored by AHC Media.
Accreditation:
AHC Media is accredited by the Accreditation Council for Continuing Medical Education to provide continuing medical education for physicians.
Credit Designation:
AHC Media designates this enduring material for a maximum of 2 AMA PRA Category 1 Credits. Physicians should claim only the credit commensurate with the extent of their participation in the activity.
Faculty
Editor
William Ershler, MD
INOVA Fairfax Hospital Cancer Center, Fairfax, VA;
Director, Institute for Advanced Studies in Aging
Washington, DC

Executive Editor
Leslie Coplin

Managing Editor
Neill Kimball

Authors
Bindu Kanapuru, MD
Institute for Advanced Studies in Aging and Geriatric Medicine
Falls Church, VA

Jerome W. Yates, MD
Hematology/Immunology Unit
National Institute on Aging, NIH

Peer Reviewer
V.R. Veerapalli, MD
Staff Clinician, INOVA Fairfax Cancer Center
Falls Church, VA


Subjects:
  • Combination Treatment with Low-Dose Protracted Temozoloamide and Bevacizumab for Heavily Pretreated Patients with Recurrent Glioblastoma
  • Erlotinib Improves Chemotherapy Response Rates for Patients with Advanced Biliary Tract Cancers
  • Managing Chemotherapy-induced 'Hot Flashes'
  • Fludarabine/Rituximab for Relapsed Hairy Cell Leukemia: Canadian Experience
  • Dose Dense Weekly Carboplatin-Paclitaxel Prior to Concurrent Chemoradiotherapy for Locally Advanced Head and Neck Cancer
 
Objectives:
  • to present the latest information regarding diagnosis and treatment of various types of cancer
  • to present prevalence/surveillance data and long-term follow-up results of chemotherapy/radiation regimens
  • to describe new advances in the field of oncology
 
Financial Disclosure:

Clinical Oncology Alert's Editor, William Ershler, MD; author Bindu Kanapuru, MD, author Jerome W. Yates, MD, peer reviewer, V.R. Veerapalli, MD; executive editor, Leslie Coplin; and managing editor, Neill Kimball report no financial relationships relevant to this field of study.

Copyright 2012 AHC Media LLC. All rights reserved.


 
  • You are not currently logged in.
  • To view content articles and complete the post-test for this course, please login or register now

 



Copyright Notices  | Terms of Use  
Privacy Statement